Innovation portfolio
Fourteen analytical innovations across four technology domains, designed as standalone products that share methodological foundations. Every one is the work of the same founder and lead developer, built in continuous succession since 2019, and priced and configured to be within reach of NHS, national-government and multilateral-institution buyers in high-income and lower-middle-income economies.
Clinical AI and Health Intelligence
Clinical decision-making in acute, primary and post-acute care runs on threshold alarms and reactive monitoring. Threshold systems report that a crisis has arrived; they do not say when one will arrive. Risk scores classify the current state but carry no time dimension. The complex polypharmacy population carries an avoidable adverse-event burden, post-acute patients are readmitted within days of discharge, and prescribing, dispensing and adherence still run across paper and partly digital systems.
Delivers: Software as a medical device, multi-platform clinical applications, wearables-based monitoring and NHS-grade decision support.
PARIS AI
A clinical decision-support suite in three componentsPARIS AI covers the patient journey in three components. PARIS AI Poly addresses polypharmacy risk. PARIS AI AEP (Acute Events Prevention, also referred to as PARIS AI ACUTE) reads the observations hospitals already record and gives care teams advance warning that a patient's condition is heading for a clinically defined threshold, with evidence of stability when it is not; one engine is configured to each clinical specialty, giving fourteen clinical domain applications and 106 use cases. PARIS-Ai Rehab follows recovery after the acute phase.
- Components
- PARIS AI Poly, PARIS AI AEP, PARIS-Ai Rehab
- Relationships
- AEP engine inherited by YOARLY; SMedRx3 integrates with the suite
- Featured product
- PARIS AI Sepsis AEP
YOARLY
The wearable form of the PARIS AI AEP engineYour Early Warning. Not a tracker or a monitor but a warning system that operates before the crisis: the same engine applied to continuous sensor streams from a wearable device, producing graduated alerts from immediate escalation to confidence over a multi-day horizon.
- Relationships
- Inherits the PARIS AI AEP engine
- Markets
- UK and West Africa
DEWLY
Earlier warning of deterioration in critical careDelivered as software as a medical device, DEWLY detects deterioration earlier than threshold-based monitoring, using the routine observations already collected in intensive care and high-dependency units. It produces three clinically distinct outputs from one analysis: a deterioration warning, a stability confirmation and a recovery forecast. It operates alongside NEWS2 without changing how observations are collected, documented or escalated.
- Setting
- Intensive care and high-dependency units
PARIS AI Poly
Polypharmacy risk intelligenceA clinical decision-support application for polypharmacy risk assessment, delivered across multiple platforms. Built on regulatory adverse-event evidence, it gives the clinician a single actionable risk tier with a defensible recommendation.
- Relationships
- PARIS AI suite; shares its adverse-event modelling discipline with RxIndex, UpLabel and MaxGeniz
RxIndex
A population-normalised medication risk indexA continuous, real-world medication risk index for the complex polypharmacy population: patients on five or more medications with three or more long-term conditions. It produces a comparative risk score for every medication in the FDA database from regulatory and real-world adverse-event evidence, delivered as interactive clinical dashboards and structured data exports.
- Relationships
- Shares its adverse-event modelling discipline with PARIS AI Poly, UpLabel and MaxGeniz
SMedRx3
Digital prescription, dispensation and adherenceEach prescription is tamper-evident and tracked from prescribing through dispensing to administration, with role-based access scoped to clinical responsibility, a full audit trail, and offline-first operation with cloud synchronisation. It addresses prescription integrity, adherence visibility and cross-facility continuity, and interoperates with electronic health records, billing and pharmacy systems where integration is implemented.
- Market
- NHS and community pharmacy
PARIS-Ai Rehab
Rehabilitation trajectory monitoring for post-acute careTracks functional recovery across the rehabilitation journey, predicts recovery trajectories, identifies setbacks before they occur and optimises the timing of intervention across eleven rehabilitation pathways, from post-stroke and cardiac to post-surgical and complex medical. Recovery is tracked separately across five functional domains rather than collapsed into a single index. Delivered across multiple platforms with end-to-end encryption.
- Relationships
- PARIS AI suite; designed to integrate with PARIS AI AEP, PARIS AI Poly and SMedRx3 in the clinical workflow
Pharmacovigilance and Drug Safety
Post-market drug safety depends on three evidence streams that are rarely brought together: official drug labels, real-world adverse-event reporting databases, and predictive intelligence. Labels reflect the regulatory baseline at approval and lag real-world signal. Spontaneous reporting systems aggregate reports but offer no predictive horizon. The complex polypharmacy population is excluded from the randomised trials whose results populate labels and guidance, so the evidence gap for these patients is structural.
Delivers: Regulator-ready gap analyses and real-world evidence at guideline standard.
UpLabel
Post-market drug surveillance for regulatorsA disease-agnostic platform that compares official drug-label content against statistical and predictive evidence derived from real-world adverse-event data, and produces structured gap analyses between the label, real-world evidence and prediction. It operates on data already held in regulatory reporting systems with no new clinical infrastructure or patient contact, and produces outputs structured for FDA, MHRA, EMA and NICE submission.
- Relationships
- Pharmacovigilance pair with MaxGeniz
MaxGeniz
Real-world evidence for the complex polypharmacy populationAn integrated data-science platform for patients with complex polypharmacy across cardiovascular disease, type 2 diabetes, mental health, cancer and obesity: the most clinically complex, most resource-intensive and least represented in the trials that inform guidance. A discovery phase characterises the population, maps medication patterns and produces hypotheses ready for confirmatory study; an evidence phase turns them into NICE-compliant real-world evidence through multi-site NHS analysis without centralising patient data, yielding causal estimates at guideline standard.
- Relationships
- Pharmacovigilance pair with UpLabel
- Markets
- NHS trusts, enterprise, MENA
Financial Intelligence and Forensics
Forensic financial detection runs on single-method tools, and none of them converges several independent detection methods into one ranked output. Due diligence on a single entity typically requires separately procured capabilities for financial-statement analysis, forensic detection, tax assessment and media monitoring, each with its own data model and output, synthesised by hand at the end.
Delivers: Ranked forensic risk and single-entity due diligence at scale.
REVEDA
The forensic detection engineREVEDA applies several independent detection methods to financial data at once and converges the outputs into the CAF Index (Changepoints, Anomalies, Fraud), a single composite forensic risk score that ranks every entity by aggregate detection signal, supporting evidence-based audit selection and regulatory escalation. It operates as a standalone tool and as the engine embedded within CREDA.
- Relationships
- Embedded in CREDA under sub-licence
CREDA
Integrated due-diligence and compliance analyticsCREDA combines company financial reports, global tax intelligence, REVEDA forensic analytics and media signals into a single compliance and risk picture for each entity. It computes financial performance, risk and compliance indicators across six proprietary metric frameworks, assesses tax liability with live global rate referencing by country, year and industry, embeds the full REVEDA engine and CAF Index, forecasts financial variables and surfaces reputational signals from news and social media. The result is the Aggregate Risk Score, one ranked composite per entity.
- Relationships
- Embeds REVEDA
- Market
- Due diligence, compliance and tax
Economic and Fiscal Intelligence
Economic and fiscal tooling for finance ministries, central banks, development banks and regional economic communities is underserved at the price point these institutions can reach, particularly in lower-middle-income economies. Existing platforms provide trend lines, growth rates and benchmarks, but no formal, reproducible measure of how a fiscal indicator, economic series or commodity trade position has structurally evolved over a defined period.
Delivers: Three platforms sharing the MDY Structural Evolution Index, MDY[SEI], as their common analytical signature.
FLOWZZ
Fiscal intelligence on IMF Government Finance StatisticsFLOWZZ takes the analyst through three progressive phases: discovery, with comparative aggregates, a hierarchical explorer of the GFS classification, multi-country time series and relative change analytics; dynamics, with moving and rolling statistics filtered by income class and geography; and decision intelligence, with fiscal forecasting, simulation and surface visualisation that identify which fiscal levers most strongly drive a target outcome.
- Relationships
- Economic intelligence trio with KERD and MERD via MDY[SEI]
- Buyers
- Fiscal analysts and policymakers
KERD
Multi-domain economic intelligenceKERD integrates World Bank development indicators, IMF government finance and international financial statistics, WTO trade datasets and international price databases into one analytical environment. Six modules share a unified architecture: macroeconomic analytics with keyword discovery and before-and-after intervention analysis; fiscal and debt time-series diagnostics and forecasting; infrastructure investment and financing analytics; merchandise, services and digital trade with comparative-advantage measures; commodity prices, price indices, exchange rates and monetary data; and price index forecasting and optimisation.
- Relationships
- Economic intelligence trio with FLOWZZ and MERD via MDY[SEI]
- Buyers
- Economists, policymakers and multilateral development banks
MERD
Agricultural-trade structural evolution on FAOSTATAn analytical platform for food and agricultural commodity trade policy built on the full FAO FAOSTAT dataset. At its core is MDY[SEI], the MDY Structural Evolution Index, a formal and reproducible measure of how an agricultural product's position within an economy has evolved over a defined horizon: for any FAO-tracked product and country it returns a structural-evolution score, a rank, a five-tier classification of change significance and boundary statistics. Seven analytical modules surround it, refreshed monthly against FAOSTAT and UN COMTRADE.
- Relationships
- Origin of MDY[SEI], reused under licence in FLOWZZ and KERD
- Users
- Ministries of agriculture and trade, the African Development Bank, FAO, the World Bank, IFAD, ECOWAS and ASEAN
In the App Store, and behind the portfolio
Applications available today, and the expertise that builds the innovations above.
HealthWalletQR
iOS appA personal health passport that works without a connection. Health data stays on the device and can be shared instantly by QR code.
App StoreFiscal Explorer
iOS appNavigate IMF Government Finance Statistics with classification search, multi-dimensional filtering and year-based groupings, built on the GFS 2014 methodology.
App StoreMERD analysis app series
iOS app seriesAgricultural analytics across the value chain, from inputs to trade and food security, with statistical and machine learning tools that work offline.
Expert services
Consultancy and developmentData science, statistical modelling, health technology validation, and iOS and macOS development, from proof of concept to deployed system.
Speak with our expertsWorking with the portfolio
Clinical partners, regulators, finance ministries and development institutions each engage with a different part of the portfolio. Tell us which, and we will send the relevant material under NDA.